> Detailanzeige

Li, Boyi; Sursal, Tolga; Martinez, Erick; Karimov, Zafar; Feldstein, Eric; Stein, Alan; Cooper, Jared; Hosein-Woodley, Rasheed; Liu, Aiden; McIntyre, Matthew; Bowers, Christian; Hanft, Simon; Hafeez, Zeeshan; Pisapia, Jared; Muh, Carrie; Tyagi, Rachana; Mayer, Stephan A.; Gandhi, Chirag D.; Al-Mufti, Fawaz

An institutional report of heparin induced thrombocytopenia type II in aneurysmal subarachnoid hemorrhage patients

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: An institutional report of heparin induced thrombocytopenia type II in aneurysmal subarachnoid hemorrhage patients
  • Beteiligte: Li, Boyi; Sursal, Tolga; Martinez, Erick; Karimov, Zafar; Feldstein, Eric; Stein, Alan; Cooper, Jared; Hosein-Woodley, Rasheed; Liu, Aiden; McIntyre, Matthew; Bowers, Christian; Hanft, Simon; Hafeez, Zeeshan; Pisapia, Jared; Muh, Carrie; Tyagi, Rachana; Mayer, Stephan A.; Gandhi, Chirag D.; Al-Mufti, Fawaz
  • Erschienen: SAGE Publications, 2023
  • Erschienen in: Interventional Neuroradiology
  • Sprache: Englisch
  • DOI: 10.1177/15910199221091643
  • ISSN: 1591-0199; 2385-2011
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:sec><jats:title>Background</jats:title><jats:p> Heparin induced thrombocytopenia Type II (HIT-II) is a dangerous thromboembolic complication of heparin therapy. The current literature on incidence and outcomes of HIT-II in aneurysmal subarachnoid hemorrhage (aSAH) patients remains sparse. </jats:p></jats:sec><jats:sec><jats:title>Objective</jats:title><jats:p> We report our institution's incidence and outcomes of HIT-II in aSAH patients. </jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p> We performed a retrospective cohort study at an academic medical center between June 2014 and July 2018. All patients had aSAH confirmed by digital subtraction angiography. Diagnosis of HIT-II was determined by positive results on both heparin PF4-platelet antibody ELISA (anti-PF4) and serotonin release assay (SRA). </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> 204 patients met inclusion criteria. Seven patients (7/204, 3.5%) underwent laboratory testing, three of whom met clinical criteria. HIT-II incidence was confirmed in two of these seven patients (2/204, 0.98%), who had high BMI and T4 scores. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> Our institution's report of HIT-II incidence in aSAH patients is lower than previously reported in this population and more closely parallels HIT-II incidence in the general and surgical ICU setting. Widely-accepted American College of Chest Physicians (ACCP) clinical diagnostic criteria in conjunction with anti-PF4 and SRA testing is the gold standard of clinical diagnosis of HIT-II in aSAH patients. </jats:p></jats:sec>